Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer's disease

  • Boza-Serrano, Antonio
  • Vrillon, Agathe
  • Minta, Karolina
  • Paulus, Agnes
  • Camprubí-Ferrer, Lluís
  • García, Megg
  • Andreasson, Ulf
  • Antonell, Anna
  • Wennström, Malin
  • Gouras, Gunnar K.
  • Dumurgier, Julien
  • Cognat, Emmanuel
  • Molina-Porcel, Laura
  • Balasa, Mircea
  • Vitorica, Javier
  • Sánchez-Valle, Raquel
  • Paquet, Claire
  • Venero, José L.
  • Blennow, Kaj
  • Deierborg, Tomas
Galectin-3 (Gal-3) is a beta-galactosidase binding protein involved in microglial activation in the central nervous system (CNS). We previously demonstrated the crucial deleterious role of Gal-3 in microglial activation in Alzheimer's disease (AD). Under AD conditions, Gal-3 is primarily expressed by microglial cells clustered around Aβ plaques in both human and mouse brain, and knocking out Gal-3 reduces AD pathology in AD-model mice. To further unravel the importance of Gal-3-associated inflammation in AD, we aimed to investigate the Gal-3 inflammatory response in the AD continuum. First, we measured Gal-3 levels in neocortical and hippocampal tissue from early-onset AD patients, including genetic and sporadic cases. We found that Gal-3 levels were significantly higher in both cortex and hippocampus in AD subjects. Immunohistochemistry revealed that Gal-3+ microglial cells were associated with amyloid plaques of a larger size and more irregular shape and with neurons containing tau-inclusions. We then analyzed the levels of Gal-3 in cerebrospinal fluid (CSF) from AD patients (n = 119) compared to control individuals (n = 36). CSF Gal-3 levels were elevated in AD patients compared to controls and more strongly correlated with tau (p-Tau181 and t-tau) and synaptic markers (GAP-43 and neurogranin) than with amyloid-β. Lastly, principal component analysis (PCA) of AD biomarkers revealed that CSF Gal-3 clustered and associated with other CSF neuroinflammatory markers, including sTREM-2, GFAP, and YKL-40. This neuroinflammatory component was more highly expressed in the CSF from amyloid-β positive (A+), CSF p-Tau181 positive (T+), and biomarker neurodegeneration positive/negative (N+/-) (A + T + N+/-) groups compared to the A + T-N- group. Overall, Gal-3 stands out as a key pathological biomarker of AD pathology that is measurable in CSF and, therefore, a potential target for disease-modifying therapies involving the neuroinflammatory response., Open access funding provided by Lund University. Vetenskapsrådet, 2019-0633, Antonio Boza Serrano, Ministerio de Ciencia, Innovación y Universidades, RTI2018-098645-B-100, Jose Luis Venero, PID2021-124096OB-100, Jose Luis Venero, Instituto de Salud Carlos III, 20/00448, Raquel Sanchez-Valle, Union PI18/01556, Javier Vitorica, PI21/00914, Javier Vitorica, Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía, P18-RT-1372, Jose Luis Venero, US-1262734, Javier Vitorica, Kungliga Fysiografiska Sällskapet i Lund, 20191114ABS, Antonio Boza Serrano, 20211129ABS, Antonio Boza Serrano, Greta och Johan Kocks stiftelser, 20201201ABS, Antonio Boza Serrano, Consejería de Economía, Conocimiento, E mpresas y Universidad, Junta de Andalucía, US-1264806, Jose Luis Venero, Peer reviewed